A subgroup of patients with osteosarcoma -- a form of bone cancer -- could be helped by an existing drug, suggest scientists. In the largest genetic sequencing study of osteosarcoma to date, scientists discovered that 10 percent of patients with a genetic mutation in particular growth factor signalling genes may benefit from existing drugs, known as IGF1R inhibitors.
Existing drugs could benefit patients with bone cancer, genetic study suggests
Jun
23
2017